The FDA approved Enspryng for thyroid eye disease, the first at-home subcutaneous option. Read how this new treatment works ...

CHMP issues second negative opinion on narsoplimab (Yartemlea) for TA-TMA, leaving European patients without an approved ...

ARPA-H awards Georgetown and Buck Institute up to $51.7M to build an AI platform predicting protein misfolding in Alzheimer's ...

First Tracks Biotherapeutics prices a $200M private placement at $32.75 per share to advance ANB033. Read the full details ...

Terumo and Oxford University launch a six-year, $9M+ organ perfusion research partnership. Discover how it could extend organ ...

Iambic Therapeutics prices IPO at $16 per share, raising $150M to advance AI-discovered HER2 inhibitor. Read the full details ...

OMass Therapeutics raised USD 310M (GBP 230M) in an oversubscribed Series C to push its MC2 antagonist into Phase II. Read ...

J&J and Triastek sign a collaboration, license and equity deal to develop novel 3D-printed oral medicines. Read the full ...

BioAge Labs and Deep Origin launch an AI-driven multi-target drug discovery deal, with validated hits in under 3 months. Read ...

Verdiva Bio halted its Phase II trial of oral ecnoglutide (VRB-101) for weight maintenance after injectable GLP-1 therapy.

Ocugen partners with Roots Pharmaceutical to bring OCU400 retinitis pigmentosa gene therapy to the Middle East and North ...

Eton Pharmaceuticals secures exclusive U.S. rights to Libervant, a diazepam buccal film for epilepsy seizure clusters. Read ...